Sagent Pharmaceuticals Inc. (SGNT) Tuesday announced the approval and launch of Zoledronic Acid Injection 4 mg, the generic form of the bisphosphonate Zometa, in a latex-free plastic vial.
According to IMS data for the 12 months ending January 2013, the U.S. market for Zoledronic Acid Injection 4 mg approximated $606 million.
Zoledronic Acid Injection 4 mg is indicated for the treatment of hypercalcemia of malignancy, patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.